- By insider

President and CEO of Regulus Therapeutics Inc (RGLS) Joseph P Hagan bought 219,780 shares of RGLS on 07/25/2017 at an average price of $0.91 a share. The total cost of this purchase was $200,000.

Regulus Therapeutics Inc is a biotechnology company that focuses on the development of microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. Regulus Therapeutics Inc has a market cap of $59.030 million; its shares were traded at around $1.11 with and P/S ratio of 85.39.

• Warning! GuruFocus has detected 5 Warning Signs with RGLS. Click here to check it out.

• RGLS 15-Year Financial Data

• The intrinsic value of RGLS

• Peter Lynch Chart of RGLS

CEO Recent Trades:

• President and CEO Joseph P Hagan bought 219,780 shares of RGLS stock on 07/25/2017 at the average price of $0.91.

CFO Recent Trades:

• CFO Daniel R. Chevallard bought 54,945 shares of RGLS stock on 07/25/2017 at the average price of $0.91.

Directors and Officers Recent Trades:

• Chief R & D Officer Timothy Michael Wright bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91.

• Director William H Rastetter bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91.

• Director Stelios Papadopoulos bought 1,000,000 shares of RGLS stock on 07/25/2017 at the average price of $0.91.

For the complete insider trading history of RGLS, click here

.This article first appeared on GuruFocus.

• Warning! GuruFocus has detected 5 Warning Signs with RGLS. Click here to check it out.

• RGLS 15-Year Financial Data

• The intrinsic value of RGLS

• Peter Lynch Chart of RGLS